Literature DB >> 4086231

Prophylactic use of topical adriamycin after transurethral resection of transitional cell bladder tumours.

J Flamm, F Grof.   

Abstract

Thirty-five patients with carcinoma of the bladder were subjected to weekly intravesical instillation treatment with 30 mg adriamycin/50 ml solution for a period of 6 weeks following transurethral resection of the tumour. The oncolytic and thus recurrence-preventive value of treatment was determined by endoscopic controls with exploratory excisions and exfoliative cytology. All in all, a recurrence-free rate was found in 77% over a minimum observation period of one year. These results are definitely better than those of comparable instillation treatments with surface-active or immunologically active substances.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4086231     DOI: 10.1007/BF02082485

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  10 in total

1.  Topical instillation of doxorubicin hydrochloride in the treatment of recurring superficial transitional cell carcinoma of the bladder.

Authors:  M D Banks; J E Pontes; R M Izbicki; J M Pierce
Journal:  J Urol       Date:  1977-11       Impact factor: 7.450

2.  [Conservative treatment of recurrent papillomatosis of the urinary bladder with vitamin A acid. Preliminary report].

Authors:  J P Evard; W Bollag
Journal:  Schweiz Med Wochenschr       Date:  1972-12-23

3.  [Influence of T-lymphocytes in bladder cancer on appearance and infiltration of recurrences (author's transl)].

Authors:  U Stöber
Journal:  Urologe A       Date:  1978-09       Impact factor: 0.639

4.  [Adjuvant local instillation with vitamin A in the therapy of bladder tumours following transurethral resection].

Authors:  J Flamm; F Grof
Journal:  Urologe A       Date:  1982-07       Impact factor: 0.639

5.  Intravesical therapy with adriamycin in patients with superficial bladder tumors.

Authors:  F Edsmyr; T Berlin; J Boman; M Duchek; P L Esposti; H Gustafsson; H Wijkström; L G Collste
Journal:  Eur Urol       Date:  1980       Impact factor: 20.096

6.  [The prognostic significance of the immune status (DNCB-test) in patients with carcinoma of the bladder, checked by observation of the course of disease (author's transl)].

Authors:  J Flamm; S Burkert
Journal:  Wien Med Wochenschr       Date:  1981

7.  Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder.

Authors:  G J Gavrell; R W Lewis; W L Meehan; G A Leblanc
Journal:  J Urol       Date:  1978-10       Impact factor: 7.450

8.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

9.  Long-term follow-up in patients with superficial bladder tumours treated with intravesical Epodyl.

Authors:  J M Fitzpatrick; O Khan; R T Oliver; P R Riddle
Journal:  Br J Urol       Date:  1979-12

10.  [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].

Authors:  J Flamm; F Grof
Journal:  Wien Med Wochenschr       Date:  1981-10-31
  10 in total
  1 in total

1.  Approaches to the treatment of bladder cancer at Stanford.

Authors:  F M Torti
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.